Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Johnson DB, Long GV, Pickering L, Larkin JMG, Blank CU, Lorigan P. Serra-Bellver P, et al. Among authors: lorigan p. Eur J Cancer. 2022 Nov;176:121-132. doi: 10.1016/j.ejca.2022.09.004. Epub 2022 Oct 7. Eur J Cancer. 2022. PMID: 36215945 Free article.
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P. O'Brien ME, et al. Among authors: lorigan p. Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16. Eur J Cancer. 2011. PMID: 21684151 Clinical Trial.
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C. Khoja L, et al. Among authors: lorigan p. J Invest Dermatol. 2013 Jun;133(6):1582-90. doi: 10.1038/jid.2012.468. Epub 2012 Dec 6. J Invest Dermatol. 2013. PMID: 23223143 Free article.
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.
Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D. Flaherty KT, et al. Among authors: lorigan p. Lancet Oncol. 2014 Mar;15(3):297-304. doi: 10.1016/S1470-2045(14)70007-5. Epub 2014 Jan 31. Lancet Oncol. 2014. PMID: 24485879 Free PMC article.
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU. Kelderman S, et al. Among authors: lorigan p. Cancer Immunol Immunother. 2014 May;63(5):449-58. doi: 10.1007/s00262-014-1528-9. Epub 2014 Mar 8. Cancer Immunol Immunother. 2014. PMID: 24609989 Free PMC article. Clinical Trial.
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ. Hamid O, et al. Among authors: lorigan p. Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26. Cancer. 2014. PMID: 24676877 Free article. Clinical Trial.
Expanded access programmes: patient interests versus clinical trial integrity.
Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Lorigan P, et al. Lancet Oncol. 2015 Jan;16(1):15-7. doi: 10.1016/S1470-2045(14)71161-1. Epub 2014 Dec 29. Lancet Oncol. 2015. PMID: 25638540 No abstract available.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Weber JS, et al. Among authors: lorigan p. Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795410 Clinical Trial.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. Among authors: lorigan p. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG. Ahmad SS, et al. Among authors: lorigan p. Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185. Melanoma Res. 2015. PMID: 26225580 Free PMC article.
297 results